Thromboembolic complications of oral oestrogen-gestagen contraception;Tromboembolické komplikace užívání orální estrogen-gestagenní antikoncepce

Vnitrni Lekarstvi

Volumn 47, Issue 7, 2001, Pages 460-464

  Smirova S ^a   Chochola, M ^a   Varejka P ^a   Aschermann, M ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Contraception; Oestrogen gestagen contraception; Thromboembolic complications; Thrombophil conditions

Indexed keywords

DESOGESTREL; DESOGESTREL PLUS ETHINYLESTRADIOL; DIANE; ESTROGEN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS GESTODENE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS LYNESTRENOL; ETHINYLESTRADIOL PLUS NORETHISTERONE; ETHINYLESTRADIOL PLUS NORGESTIMATE; ETHINYLESTRADIOL PLUS NORGESTREL; GESTAGEN; GESTODENE; LEVONORGESTREL; LYNESTRENOL; LYNESTRENOL PLUS MESTRANOL; NORGESTREL; ORAL CONTRACEPTIVE AGENT; TRISISTON;

BLOOD CLOTTING; DEEP VEIN THROMBOSIS; FEMALE; HUMAN; LUNG EMBOLISM; ORAL CONTRACEPTION; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; THROMBOEMBOLISM; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FIBRINOLYSIS;

BLOOD COAGULATION; CONTRACEPTIVES, ORAL, COMBINED; FEMALE; FIBRINOLYSIS; HUMANS; THROMBOEMBOLISM;

EID: 0034945345     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Venous tromboembolic disease and combine oral contraceptives: Results of international multicentre case-control study
2. Hormonální antikoncepce a tromboembolická nemoc I. Epidemiologická data
3. Hormonální antikoncepce a tromboembolická nemoc II. Patofysiologický podklad
4. Effects of newer oral contraceptives on the inhibition of coagulation and fibrinolysis in relation to dosage and type of steroid
5. Effect of oral contraceptives on haemostasis variables
6. Pulmonary embolism
7. Oral contraceptive estrogen dose and the risk of deep venous tromboembolic disease
8. Leidenská mutace faktoru V u uživatelek hormonální antikoncepce
9. A common genetic variation in the 3′untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increased in venous trombosis
10. Resistance to activated protein C as a basis for venous tromboembolism associated with pregnancy and oral contraceptives
11. Cost-effectiveness of factor V Leiden screening among oral contraceptive users
12. Activated protein C resistence assay when applied in the general populatin
13. Increased risk of venous trombosis in oral contraceptive users who are carrieres of factor V Leiden mutation
14. Doporučení pro diagnostiku a léčbu žilních chorob
15. Third generation oral contraceptives and risk of venous tromboembolic disorders: An international case-control study
16. Oral contraceptives and hormonal replacement therapy cause an imbalance in coagulation and fibrinolysis which may explain the increased risk of venous tromboembolism
17. Oral contraceptives and venous trombosis: Different sensitivities to activated protein C in women using second and third generation oral contraceptives
18. Effect of 1995 pill scare on rates of venous tromboembolism among women taking combined oral contraceptives: Analysis of general practice research database
19. Factor V Leiden: Should we screen oral contraceptive users and pregnant women?
20. Venous trombosis: A multicausal disease
21. Risk of venous tromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: Cohort and case control analysis
22. Tromboembolické komplikace kontracepce byly znovu potvrzeny
23. Oral contraception and venous tromboembolism: A case control study